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INTRODUCTION
Heart transplantation (HTx) is an established line of treat-
ment for advanced heart failure (HF), but with a shortage of 
donor organs its impact is limited. Therefore, the demand for 
efficacious and safe mechanical left ventricular assist devices 
(LVADs) is increasing. Trials with the latest-generation LVADs 
have reported survival rates of 85% to 92% [1]. According to 
leading European and American societies, LVADs are an estab-
lished therapy for end-stage HF [2, 3]. However, LVAD-related 
complications are still common and include pump thrombo-
sis, HF worsening (HFW), right ventricular failure (RV-HF), 
drive-line infections (DRI), stroke, and bleeding. 
Polish data on LVADs are scarce [4]. Since 1988, more 
than 500 HTxs have been performed at the John Paul II Hos-
pital in Krakow. In October 2015, an LVAD programme was 
initiated. The aim of this study is to report up-to-date data on 
LVADs, including survival rates and complications. 
METHODS 
This is a prospective, all-comers study of 32 consecutive pa-
tients who underwent LVAD implantation between November 
2015 and October 2017. All data collected were based on 
hospitalisation and outpatient records. The study was ap-
proved by the local Ethics Committee. 
We created an end-stage HF team, which included 
cardio-surgeons (B.K. and K.W.), cardiologists, cardio-anaes-
thetists, and associated personnel. Upon discharge, patients 
and their families were informed about LVAD management 
and provided with a 24/7 telephone line. 
The primary endpoint was composed of death and pump 
thrombosis. Secondary (safety) endpoints included: RV-HF, 
urgent hospitalisation due to HFW, DRI, and bleedings. 
Statistical analysis
Cox proportional hazards models were used to calculate 
hazard ratios (HRs) and 95% confidence intervals (CIs) for 
the primary endpoint, its individual component events, and 
secondary endpoints. Survival data were analysed using the 
Kaplan-Meier method and compared with the log-rank test. To 
examine the associations of selected variables with endpoints 
of interest (unadjusted analyses and analyses adjusted for age, 
INTERMACS score, and N-terminal pro–B-type natriuretic 
peptide [NT-proBNP] level) Cox proportional hazards models 
were used. All the analyses were conducted in R software, 
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version 3.3.2 (R Foundation for Statistical Computing, Vienna, 
Austria). All results were considered statistically significant 
when p was < 0.05.
RESULTS AND DISCUSSION 
The baseline characteristics of the study population, divided 
according to HF aetiology into ischaemic (n = 15) and di-
lated cardiomyopathy (DCM, n = 17), showed that men 
constituted the majority (94%) (Suppl. Table 1 — see journal 
website). New York Heart Association class (ischaemic HF: 
4 ± 0.3 vs. DCM: 3.8 ± 0.4; p = NS) and INTERMACS scores 
(2.8 ± 0.4 vs. 2.7 ± 0.7; p = NS) were similar. The left ventric-
ular (LV) cavity was larger in the DCM group (79.3 ± 13.1 mm 
vs. 71.7 ± 6.5 mm; p < 0.05), but the ejection fraction was 
comparable (13.3% ± 3.8% vs. 13.8% ± 3.4%; p = NS). 
NT-proBNP levels were significantly higher in the DCM group 
(8960 ± 10108 pg/mL vs. 3323 ± 2294 pg/mL; p < 0.05).
During the observational period of 12.2 ± 7.3 months, 
primary endpoint occurred in eight (24%) patients; death was 
reported in four (12%), and pump thrombosis in four (12%). 
Endpoints were analysed in all patients and subdivided into 
three categories: (1) according to HF aetiology: ischaemic 
vs. non-ischaemic, (2) INTERMACS score 1–2 vs. 3, and 
(3) first 16 vs. last 16 patients (Table 1). Patients stratified 
according to HF aetiology or INTERMACS were similar in 
terms of the of the primary endpoint. However, primary 
endpoint was more common in the first half compared to 
the second half of the population (7 [43.7%] vs. 1 [6.2%]; 
HR 0.086; 95% CI 0.009–0.81; p < 0.05). With regard to 
the primary endpoint components, numbers of deaths were 
comparable between the groups (3 [18.7%] vs. 1 [6.2%]; HR 
0.29; 95% CI 0.03–3.13; p = NS), whereas pump thrombosis 
was more frequent in the first half compared to the second 
half of patients (4 [25%] vs. 0 [0%]; p < 0.05). None of the 
following variables were predictors of the primary endpoint: 
LVAD type, prior cardiac arrest, chronic kidney disease (CKD), 
atrial fibrillation, patent foramen ovale (PFO), or the levels of 
haemoglobin, creatinine, urea, creatine kinase (CK), CK-MB, 
D-dimer, troponin, and C-reactive protein. 
Right ventricular failure was observed in nine (27.3%) 
patients and was similarly distributed in patients grouped ac-
cording to HF aetiology and INTERMACS. However, RV-HF 
was more common in the first 16 LVAD recipients (7 [43.7%] 
vs. 2 [12.5%]; HR 0.18; 95% CI 0.03–0.95; p < 0.05). PFO 
was the only independent predictor of RV-HF in a model 
adjusted for age, INTERMACS score and NT-proBNP level 
(HR 35.8; 95% CI 1.33–969.8; p < 0.05). 
Hospitalisation due to HFW occurred in 12 (40%) 
patients. HFW was more common in the first half of the 
population (9 [56%] vs. 3 [18.7%]; p < 0.05). Only CKD was 
an independent predictor of HFW in an adjusted model (HR 
1.86; 95% CI 1.08–3.96; p < 0.05). 
Drive-line infections and bleeding complications oc-
curred in 11 (34%) and eight (24%) patients, respectively. The 
frequencies of both complications were similar in all three 
patient subgroups. 
The LVAD registries report similar baseline characteristics 
of the device recipients, and the frequency of ischaemic HF 
Table 1. Comparisons of primary and secondary endpoints in patients stratified according to heart failure (HF) aetiology,  
INTERMACS score, and time of left ventricular assist device implantation
DCM
(n = 17)
ICM
(n = 15)
INTERMACS
1–2 (n = 7)
INTERMACS
> 3 (n = 25)
First 16 Last 16
Primary endpoint 
HR, 95% CI
5 (29.4)
1
3 (20)
0.6 (0.12–3.1)
1 (14.3)
1
7 (28)
2.3 (0.24–23)
7 (43.7)
1*
1 (6.2)
0.086 (0.009–0.81)*
Death
HR, 95% CI
3 (17.6)
1
1 (6.7)
0.3 (0.03–3.6)
1 (14.3)
1
3 (12)
0.82 (0.07–9.3)
3 (18.7)
1
1 (6.2)
0.29 (0.03–3.13)
Pump thrombosis
HR, 95% CI
2 (11.8)
1
2 (13.3)
1.15 (0.14–9.4)
0 (0)
1
4 (16)
> 1000 (< 0.01– > 100)
4 (25)
1*
0 (0)
< 0.001 (< 0.01–> 100)*
RV failure
HR, 95% CI
5 (29.4)
1
4 (26.7)
0.87 (0.19–4.1)
2 (28.6)
1
7 (28)
0.97 (0.15–6.2)
7 (43.7)
1*
2 (12.5)
0.18 (0.03–0.95)*
HF worsening
HR, 95% CI
6 (35.3)
1
6 (40)
1.2 (0.29–5.1)
1 (14.3)
1
11 (44)
4.7 (0.5–45.2)
9 (56)
1*
3 (18.7)
0.18 (0.04–0.9)*
Bleedings
HR, 95% CI
3 (17.6)
1
5 (33.3)
2.3 (0.45–12.1)
1 (14.3)
1
7 (28)
2.3 (0.24–23.04)
5 (31.2)
1
3 (18.7)
0.51 (0.1–2.62)
Infections
HR, 95% CI
5 (29.4)
1
6 (40)
1.6 (0.4–6.9)
3 (42.8)
1
8 (32)
0.63 (0.1–3.5)
5 (31.2)
1
6 (37.5)
1.3 (0.3–5.7)
Data are shown as number (percentage); CI — confidence interval; DCM — dilated cardiomyopathy; HR — hazard ratio; ICM — ischaemic  
cardiomyopathy; RV — right ventricular; p-values for comparison between subgroups: *p < 0.05
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and DCM is almost 50/50. Recent years have seen a shift to-
wards implanting less seriously ill patients (INTERMACS 3–5) 
as compared to the historical pattern of LVAD implantations 
in morbid/dying patients (INTERMACS 1–2) [5]. 
In the early LVAD trial, REMATCH (1998–2001), one-year 
survival estimates were 52% in the LVAD compared to 25% in 
the medical group [6]. According to the INTERMACS registry 
(2008–2014), one- and two-year survival of 12,030 LVAD 
patients was 80% and 70%, respectively [1, 5]. In the re-
cent MOMENTUM 3 (2014–2015) trial 13 (8.5%) out of 
152 HeartMate3 and 14 (9.8%) out of 142 HeartMateII pa-
tients died within six months [7]. Our results are concordant 
with the published reports. Furthermore, we observed a strik-
ing 91.4% relative risk reduction in the primary endpoint in 
the 16 patients implanted later.
In the early days, pump thrombosis was reported in almost 
20% of patients but has been reduced to the current incidence 
of 10% to 12%. We reported the occurrence of pump thrombosis 
in four (12%) patients, which is comparable to the current rates.
Left ventricular assist device supports the systemic ventri-
cle; thus, RV function is crucial for recovery. The frequency of 
RV-HF after LVAD implantation is reported at 35% [8]. Surpris-
ingly, we observed, for the first time, that RV-HF was indepen-
dently associated with the presence of PFO. The mechanisms 
of this association are unknown. We speculate that during the 
progression of LV dysfunction, an increase in left atrial pressure 
could have resulted in the PFO opening, leading to an intera-
trial shunt. An increase in RV volume may have an additional 
damaging effect on RV morphology and function.
Apart from the difficulties of continuous anticoagulation 
with vitamin K antagonists, over time LVAD recipients develop 
acquired von Willebrand disease. At the same time, many 
patients develop arteriovenous malformations in the mucosa 
of the gastrointestinal tract. Taken together, LVAD patients 
are predisposed to bleedings. In the early REMATCH trail, 
the frequency of bleeding was 42% [8]. Clinically relevant 
bleeding, which is a typical complication, occurred in eight 
(24%) patients from our cohort. 
Patients with LVADs are particularly predisposed to DRI. 
The typical site of infection is the exit site of the driveline. DRIs 
were reported in 17 (12%) and sepsis in 16 (11.4%) patients 
out of 140 subjects from the INTERMACS registry [1, 5]. 
In conclusion, a long-term LVAD programme is feasible in 
the Polish medical system; however, it requires a highly-spe-
cialised cardiac centre. The safety profile is comparable to that 
in experienced Western centres. Over 91% risk reduction in 
the latter half of patients supports a learning curve and ac-
cumulation of experience. Newly-found associations between 
PFO and RV-HF need further exploration. 
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